Doxorubicin Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100280a

CAS#: 23214-92-8 (free base)

Description: Doxorubicin free base, also called doxorubicin, is an anthracycline antibiotic with antineoplastic activity. Approved API for cancer therapeutic use doxorubicin HCl. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Note: Doxorubicin free base has low solubility in common solvents.

Price and Availability


USD 150
USD 550
USD 1850

USD 250
USD 950
USD 2950

USD 350
USD 1250
Ask price

Doxorubicin free base, purity > 95%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 50g may be 1 month.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 100280a
Name: Doxorubicin Free Base
CAS#: 23214-92-8 (free base)
Chemical Formula: C27H29NO11
Exact Mass: 543.17406
Molecular Weight: 543.52
Elemental Analysis: C, 59.66; H, 5.38; N, 2.58; O, 32.38.

Related CAS #: 23214-92-8 (free base)   25316-40-9 (HCl)    

Synonym: ADR; chloridrato de doxorrubicina. Adriamycin; Adriacin; Adriblastina; Adriblastine; Adrimedac; DOXOCELL; Doxolem; Doxorubin; Farmiblastina; Rubex. Abbreviations: ADM; Adria; DOX. Code name: FI106;

IUPAC/Chemical Name: (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione.


InChi Code: InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1

SMILES Code: O=C1C2=C(O)C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)=C3C(O)=C2C(C5=C1C=CC=C5OC)=O

Technical Data

Deep-red t0 black solid powder

>95% (or refer to the Certificate of Analysis)

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

This product has low solubility in all common solvents.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO at low concentration.

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Zhong YJ, Shao LH, Li Y. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). Int J Oncol. 2013 Feb;42(2):373-83. doi: 10.3892/ijo.2012.1754. Epub 2012 Dec 28. Review. PubMed PMID: 23291656; PubMed Central PMCID: PMC3583876.

2: Xi L, Zhu SG, Das A, Chen Q, Durrant D, Hobbs DC, Lesnefsky EJ, Kukreja RC. Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications. Nitric Oxide. 2012 May 15;26(4):274-84. doi: 10.1016/j.niox.2012.03.006. Epub 2012 Apr 5. Review. PubMed PMID: 22484629; PubMed Central PMCID: PMC3360792.

3: Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012 Jun;52(6):1213-25. doi: 10.1016/j.yjmcc.2012.03.006. Epub 2012 Mar 21. Review. PubMed PMID: 22465037.

4: Prados J, Melguizo C, Ortiz R, Vélez C, Alvarez PJ, Arias JL, Ruíz MA, Gallardo V, Aranega A. Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy. Anticancer Agents Med Chem. 2012 Nov;12(9):1058-70. Review. PubMed PMID: 22339066.

5: Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta MT, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini CA, Veronesi A. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori. 2011 Nov-Dec;97(6):690-2. doi: 10.1700/1018.11082. Review. PubMed PMID: 22322832.

6: Khasraw M, Bell R, Dang C. Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast. 2012 Apr;21(2):142-9. doi: 10.1016/j.breast.2011.12.012. Epub 2012 Jan 17. Review. PubMed PMID: 22260846.

7: Rakowski JA, Ahmad S, Holloway RW. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts. Expert Rev Anticancer Ther. 2012 Jan;12(1):31-40. doi: 10.1586/era.11.187. Review. PubMed PMID: 22149430.

8: Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs. 2011 Dec 24;71(18):2531-58. doi: 10.2165/11207510-000000000-00000. Review. PubMed PMID: 22141391.

9: Meng L, Zhang X, Lu Q, Fei Z, Dyson PJ. Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors. Biomaterials. 2012 Feb;33(6):1689-98. doi: 10.1016/j.biomaterials.2011.11.004. Epub 2011 Dec 2. Review. PubMed PMID: 22137127.

10: Maeda M, Mabuchi S, Matsumoto Y, Hisamatsu T, Ohashi H, Kimura T. Activity of pegylated liposomal doxorubicin for extragenital mullerian adenosarcoma with sarcomatous overgrowth: a case report and a review of the literature. Eur J Gynaecol Oncol. 2011;32(5):542-6. Review. PubMed PMID: 22053671.